Latest Cutaneous Lupus Erythematosus News

Page 2 of 2
Noxopharm Limited has successfully completed the second dose cohort in its HERACLES Phase 1 trial for SOF-SKN™, confirming safety and tolerability and moving forward to a higher dose. This progress marks a key step in developing a novel autoimmune disease treatment.
Ada Torres
Ada Torres
11 Aug 2025
Noxopharm Limited has successfully completed the first low-dose cohort in its HERACLES clinical trial for SOF-SKN™, clearing the way for higher dose testing in autoimmune disease treatment.
Ada Torres
Ada Torres
28 July 2025
Noxopharm has secured ethics approval to commence the HERACLES trial, marking the first human study of its novel SOF-SKN™ drug aimed at chronic inflammatory diseases.
Ada Torres
Ada Torres
29 May 2025
Noxopharm’s December 2024 quarterly report reveals expanding global interest in its Sofra technology through new Material Transfer Agreements and a strengthened cash position following a significant R&D tax rebate.
Ada Torres
Ada Torres
29 Jan 2025

Browse the archive

Full archive